Mechanistically,PPP1R17overexpression in normal murine pituitary cells recapitulated the adenoma phenotype, and PPP1R17-mediated tumorigenesis was reversible using an FDA-approved small molecule PP2A agonist both in-vitro and in-vivo. This evidence concerns the gene PPP1R17 and adenoma.